ABBREVIATIONS: APC(s) = apheresis platelet concentrate(s); PBPC(s) = peripheral blood progenitor cell(s).
High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose
Article first published online: 23 MAY 2002
Volume 42, Issue 4, pages 443–450, April 2002
How to Cite
Lefrère, F., Delarue, R., Somme, D., Levy, V., Damaj, G., Tu, A., Porcher, R., Audat, F., Boulat, C., Cavazzana-Calvo, M., Buzyn, A., Belanger, C., Maillard, N., Hermine, O. and Varet, B. (2002), High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion, 42: 443–450. doi: 10.1046/j.1525-1438.2002.00060.x
Reprint requests to: François Lefrère, MD, Service d'Hématologie Adultes, Groupe Hospitalier Necker-Enfants Malades, 149-161 rue de Sèvres, 75743 Paris Cedex 15, France; e-mail: firstname.lastname@example.org.
- Issue published online: 23 MAY 2002
- Article first published online: 23 MAY 2002
- Received for publication May 21, 2001; revision received December 6, 2001, and accepted December 14, 2001.
Options for accessing this content:
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!